Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 104Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 41Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Irinotecan 21Capecitabine 19Leucovorin 18Fulvestrant 18Cetuximab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fluorouracil 17Docetaxel 17Bevacizumab 17Drug Therapy 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Genetic Profile × 1 year × Clear all
NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

SWOG Cancer Research Network

Phase NA Active not recruiting
1,284 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡